|
US4418068A
(en)
|
1981-04-03 |
1983-11-29 |
Eli Lilly And Company |
Antiestrogenic and antiandrugenic benzothiophenes
|
|
TW366342B
(en)
|
1992-07-28 |
1999-08-11 |
Lilly Co Eli |
The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
|
|
US5478847A
(en)
|
1994-03-02 |
1995-12-26 |
Eli Lilly And Company |
Methods of use for inhibiting bone loss and lowering serum cholesterol
|
|
US5880137A
(en)
|
1996-04-19 |
1999-03-09 |
American Home Products Corporation |
2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
|
|
US5780497A
(en)
|
1996-04-19 |
1998-07-14 |
American Home Products Corporation |
2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
|
|
US5998402A
(en)
|
1996-04-19 |
1999-12-07 |
American Home Products Corporation |
2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
|
|
TW397821B
(en)
|
1996-04-19 |
2000-07-11 |
American Home Produits Corp |
3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US6005102A
(en)
|
1997-10-15 |
1999-12-21 |
American Home Products Corporation |
Aryloxy-alkyl-dialkylamines
|
|
US6326392B1
(en)
|
1997-11-06 |
2001-12-04 |
American Home Products Corporation |
Anti-estrogen plus progestin containing oral contraceptives
|
|
ID24568A
(id)
|
1997-11-06 |
2000-07-27 |
American Home Prod |
Kontrasepsi oral yang mengandung anti-estrogen plus progestin
|
|
TR200101502T2
(tr)
|
1998-03-16 |
2002-06-21 |
Celgene Corporation |
2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
|
|
US6479535B1
(en)
|
1998-05-15 |
2002-11-12 |
Wyeth |
2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
|
|
US6583170B1
(en)
|
1998-05-15 |
2003-06-24 |
Wyeth |
2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
|
|
US6045501A
(en)
|
1998-08-28 |
2000-04-04 |
Celgene Corporation |
Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
|
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
|
CO5271697A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
|
|
CO5271709A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
|
|
CO5271696A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Procedimiento para reducir la morbilidad y el riesgo de mortalidad
|
|
CO5251465A1
(es)
|
2000-01-26 |
2003-02-28 |
Pfizer Prod Inc |
Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
|
|
US20020013327A1
(en)
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
|
WO2002003986A2
(en)
|
2000-07-06 |
2002-01-17 |
Wyeth |
Use of substituted indole compounds for treating breast disorders
|
|
WO2002003989A2
(en)
|
2000-07-06 |
2002-01-17 |
Wyeth |
Use of substituted indole compounds for treating sphincter incontinence
|
|
AU7178301A
(en)
|
2000-07-06 |
2002-01-21 |
American Home Prod |
Methods for increasing nitric oxide synthase activity
|
|
AU2001273144A1
(en)
|
2000-07-06 |
2002-01-21 |
Wyeth |
Use of substituted indole compounds for treating neuropeptide y-related conditions
|
|
MXPA03000170A
(es)
|
2000-07-06 |
2003-05-27 |
Wyeth Corp |
Combinaciones de un inhibidor de recaptacion de serotonina selectivo y agentes estrogenicos.
|
|
AU2001271784A1
(en)
|
2000-07-06 |
2002-01-21 |
Wyeth |
Therapy for prosthesis-related bone degeneration
|
|
WO2002003990A2
(en)
|
2000-07-06 |
2002-01-17 |
Wyeth |
Use of substituted insole compounds for treating excessive intraocular pressure
|
|
AU2001271785A1
(en)
|
2000-07-06 |
2002-01-21 |
American Home Products Corporation |
Combinations of statins, estrogenic agents and optionally estrogens
|
|
AU2001273125A1
(en)
|
2000-07-06 |
2002-01-21 |
American Home Products Corporation |
Combinations of bisphosphonates, estrogenic agents and optionally estrogens
|
|
AR030064A1
(es)
|
2000-07-06 |
2003-08-13 |
Wyeth Corp |
Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
|
|
EP1177787A3
(en)
|
2000-07-28 |
2003-09-10 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating cataracts
|
|
JP2004507465A
(ja)
|
2000-08-11 |
2004-03-11 |
ワイス |
エストロゲン受容体陽性癌腫の治療方法
|
|
EP1192945A3
(en)
|
2000-09-21 |
2004-03-03 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating osteoarthritis
|
|
IL145838A
(en)
|
2000-10-16 |
2008-11-03 |
Pfizer Prod Inc |
Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
|
|
US6315720B1
(en)
|
2000-10-23 |
2001-11-13 |
Celgene Corporation |
Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
|
|
AU781168B2
(en)
|
2001-01-26 |
2005-05-12 |
Pfizer Products Inc. |
Method of treating certain cancers using an estrogen agonist/antagonist
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US7230012B2
(en)
|
2002-11-14 |
2007-06-12 |
Celgene Corporation |
Pharmaceutical compositions and dosage forms of thalidomide
|
|
AU2006206446A1
(en)
|
2005-01-21 |
2006-07-27 |
Janssen Pharmaceutica N.V. |
Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
|
|
JP5315060B2
(ja)
|
2006-02-03 |
2013-10-16 |
バイオノミックス リミテッド |
置換ベンゾフラン、ベンゾチオフェン、ベンゾセレノフェンおよびインドールおよびそれらのチューブリン重合阻害剤としての使用
|
|
CL2007002218A1
(es)
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
|
BRPI1007855B1
(pt)
|
2009-05-19 |
2020-03-10 |
Celgene Corporation |
Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona
|
|
US9556426B2
(en)
|
2009-09-16 |
2017-01-31 |
Celgene Avilomics Research, Inc. |
Protein kinase conjugates and inhibitors
|
|
RS56042B1
(sr)
|
2010-06-10 |
2017-09-29 |
Seragon Pharmaceuticals Inc |
Modulatori estrogenih receptora i njihove upotrebe
|
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
|
US10005750B2
(en)
|
2010-10-06 |
2018-06-26 |
J-Pharma Co., Ltd. |
Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
|
|
CA2819299A1
(en)
|
2010-12-24 |
2012-06-28 |
Merck Sharp & Dohme B.V. |
N-substituted azetidine derivatives
|
|
WO2013090829A1
(en)
|
2011-12-14 |
2013-06-20 |
Aragon Pharmaceuticals, Inc. |
Estrogen receptor modulators and uses thereof
|
|
EP2791128A4
(en)
|
2011-12-16 |
2015-04-22 |
Olema Pharmaceuticals Inc |
NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
|
|
ES2872967T3
(es)
|
2012-06-29 |
2021-11-03 |
Celgene Corp |
Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
|
|
WO2014019176A1
(zh)
|
2012-08-01 |
2014-02-06 |
华为技术有限公司 |
用于同步的方法、装置及系统
|
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
|
UY35590A
(es)
|
2013-05-28 |
2014-11-28 |
Astrazeneca Ab |
Nuevos compuestos para el tratamiento del cáncer
|
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
|
CA2915534A1
(en)
|
2013-06-19 |
2014-12-24 |
Seragon Pharmaceuticals, Inc. |
Azetidine estrogen receptor modulators and uses thereof
|
|
EA031077B1
(ru)
|
2013-06-19 |
2018-11-30 |
Серагон Фармасьютикалз, Инк. |
Модулятор рецептора эстрогена и его применения
|
|
WO2014203132A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Substituted benzopyran compounds, compositions and uses thereof
|
|
WO2015136016A2
(en)
|
2014-03-13 |
2015-09-17 |
F. Hoffmann-La Roche Ag |
Therapeutic combinations with estrogen receptor modulators
|
|
RU2738833C9
(ru)
|
2014-04-14 |
2022-02-28 |
Арвинас, Оперэйшнз, Инк. |
Имидные модуляторы протеолиза и способы их применения
|
|
EP3827836A1
(en)
|
2014-06-27 |
2021-06-02 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|
|
TWI874834B
(zh)
|
2014-12-18 |
2025-03-01 |
瑞士商赫孚孟拉羅股份公司 |
四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
|
|
WO2016105518A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
EP3270917A4
(en)
|
2015-03-18 |
2018-08-08 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
CA2988414C
(en)
|
2015-06-04 |
2023-09-26 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
EP3319944A4
(en)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
|
|
BR112017028269A2
(pt)
|
2015-07-13 |
2018-09-04 |
Arvinas Inc |
composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
|
|
BR112018000808A2
(pt)
|
2015-07-16 |
2018-09-04 |
Array Biopharma Inc |
compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
GB201516243D0
(en)
|
2015-09-14 |
2015-10-28 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
SG11201808728QA
(en)
|
2016-04-06 |
2018-11-29 |
Univ Michigan Regents |
Mdm2 protein degraders
|
|
KR20180132861A
(ko)
|
2016-04-12 |
2018-12-12 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
Bet 단백질 분해제
|
|
ES2990061T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros espirocíclicos para la degradación de proteínas diana
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
EP3454856B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
WO2017197056A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
|
US20180072711A1
(en)
|
2016-09-15 |
2018-03-15 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
TWI752098B
(zh)
|
2016-10-10 |
2022-01-11 |
美商亞雷生物製藥股份有限公司 |
作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
TWI704148B
(zh)
|
2016-10-10 |
2020-09-11 |
美商亞雷生物製藥股份有限公司 |
作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
CN110506039A
(zh)
|
2016-10-11 |
2019-11-26 |
阿尔维纳斯股份有限公司 |
用于雄激素受体靶向降解的化合物和方法
|
|
MX2019005007A
(es)
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
|
BR112019011200B1
(pt)
|
2016-12-01 |
2021-12-28 |
Arvinas Operations, Inc |
Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
JP2020505327A
(ja)
|
2016-12-23 |
2020-02-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
|
|
KR20250117470A
(ko)
|
2016-12-23 |
2025-08-04 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
WO2018136661A1
(en)
*
|
2017-01-18 |
2018-07-26 |
Andrews Steven W |
SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
|
|
WO2018136663A1
(en)
|
2017-01-18 |
2018-07-26 |
Array Biopharma, Inc. |
Ret inhibitors
|
|
BR112019015312A2
(pt)
|
2017-01-26 |
2020-03-10 |
Arvinas Operations, Inc. |
Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
|
|
IL312367A
(en)
|
2017-01-31 |
2024-06-01 |
Arvinas Operations Inc |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2018226542A1
(en)
|
2017-06-09 |
2018-12-13 |
Arvinas, Inc. |
Modulators of proteolysis and associated methods of use
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
EP3658548A1
(en)
|
2017-07-28 |
2020-06-03 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
TWI783057B
(zh)
|
2017-10-10 |
2022-11-11 |
美商絡速藥業公司 |
製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法
|
|
TWI876442B
(zh)
|
2017-10-10 |
2025-03-11 |
美商絡速藥業公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
|
|
CN111372585A
(zh)
*
|
2017-11-16 |
2020-07-03 |
C4医药公司 |
用于靶蛋白降解的降解剂和降解决定子
|
|
EP3710443A1
(en)
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
LT3728271T
(lt)
|
2017-12-19 |
2022-12-12 |
Turning Point Therapeutics, Inc. |
Makrocikliniai junginiai, skirti ligų gydymui
|
|
US11472802B2
(en)
|
2018-01-18 |
2022-10-18 |
Array Biopharma Inc. |
Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
|
|
JP7060694B2
(ja)
|
2018-01-18 |
2022-04-26 |
アレイ バイオファーマ インコーポレイテッド |
Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
|
|
EP3740490A1
(en)
|
2018-01-18 |
2020-11-25 |
Array Biopharma, Inc. |
Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
|
|
EP3773576A4
(en)
|
2018-03-26 |
2021-12-29 |
C4 Therapeutics, Inc. |
Cereblon binders for the degradation of ikaros
|
|
US20190300521A1
(en)
|
2018-04-01 |
2019-10-03 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
WO2019195609A2
(en)
|
2018-04-04 |
2019-10-10 |
Arvinas Operations, Inc. |
Modulators of proteolysis and associated methods of use
|
|
IL302595A
(en)
|
2018-04-13 |
2023-07-01 |
Arvinas Operations Inc |
Servalon ligands and bifunctional compounds containing them
|
|
EP3781156A4
(en)
|
2018-04-16 |
2022-05-18 |
C4 Therapeutics, Inc. |
SPIROCYCLIC COMPOUNDS
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
WO2020023851A1
(en)
|
2018-07-26 |
2020-01-30 |
Yale University |
Bifunctional substitued pyrimidines as modulators of fak proteolyse
|
|
JP7297053B2
(ja)
|
2018-08-20 |
2023-06-23 |
アルビナス・オペレーションズ・インコーポレイテッド |
神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
|
|
WO2020051235A1
(en)
*
|
2018-09-04 |
2020-03-12 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
|
IL281188B2
(en)
|
2018-09-07 |
2025-08-01 |
Arvinas Operations Inc |
Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
CN112996794A
(zh)
|
2018-09-10 |
2021-06-18 |
阿雷生物药品公司 |
作为ret激酶抑制剂的稠合杂环化合物
|
|
WO2020114487A1
(en)
*
|
2018-12-07 |
2020-06-11 |
Sunshine Lake Pharma Co., Ltd. |
Ret inhibitors, pharmaceutical compositions and uses thereof
|
|
CN120698983A
(zh)
*
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
ES2995214T3
(en)
|
2019-03-06 |
2025-02-07 |
C4 Therapeutics Inc |
Heterocyclic compounds for medical treatment
|
|
WO2020210630A1
(en)
|
2019-04-12 |
2020-10-15 |
C4 Therapeutics, Inc. |
Tricyclic degraders of ikaros and aiolos
|
|
JP2023511471A
(ja)
|
2019-10-28 |
2023-03-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二官能性化合物
|
|
JP2023511472A
(ja)
|
2019-10-29 |
2023-03-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための二官能性化合物
|
|
KR20220119415A
(ko)
|
2019-12-20 |
2022-08-29 |
씨4 테라퓨틱스, 인코포레이티드 |
Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물
|